{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:52:51Z","timestamp":1767851571210,"version":"3.49.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011747","name":"Novo Nordisk Foundation Center for Basic Metabolic Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:p>Because of differential processing of the hormone precursor, proglucagon, numerous peptide products are released from the pancreatic alpha cells and the intestinal L-cells in which the (pro)glucagon gene is expressed. Of particular interest in relation to obesity are glucagon from the pancreas and oxyntomodulin and GLP-1 from the gut, all of which inhibit food intake, but the other products are also briefly discussed, because knowledge about these is required for selection and evaluation of the methods for measurement of the hormones. The distal intestinal L-cells also secrete the appetite-inhibiting hormone PYY. Characteristics of the secretion of the pancreatic and intestinal products are described, and causes of the hypersecretion of glucagon in obesity and type 2 diabetes are discussed. In contrast, the secretion of the products of the L-cells is generally impaired in obesity, raising questions about their role in the development of obesity. It is concluded that the impairment probably is secondary to obesity, but the lower plasma levels may contribute to the development.<\/jats:p>","DOI":"10.3389\/fnut.2022.964406","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T05:54:32Z","timestamp":1659592472000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity"],"prefix":"10.3389","volume":"9","author":[{"given":"Jens Juul","family":"Holst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"838410","DOI":"10.3389\/fendo.2022.838410","article-title":"Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes","volume":"13","author":"Tan","year":"2022","journal-title":"Front Endocrinol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"18827","DOI":"10.1016\/S0021-9258(17)32241-X","article-title":"Proglucagon processing in porcine and human pancreas","volume":"269","author":"Holst","year":"1994","journal-title":"J Biol Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1432-1033.1987.tb11162.x","article-title":"Identical mRNA for preproglucagon in pancreas and gut","volume":"164","author":"Novak","year":"1987","journal-title":"Eur J Biochem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"12826","DOI":"10.1016\/S0021-9258(18)51561-1","article-title":"Complete sequences of glucagon-like peptide-1 from human and pig small intestine","volume":"264","author":"Orskov","year":"1989","journal-title":"J Biol Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1210\/endo-119-4-1467","article-title":"Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas","volume":"119","author":"Orskov","year":"1986","journal-title":"Endocrinology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/400_2009_35","article-title":"Glucagon and glucagon-like peptides 1 and 2","volume":"50","author":"Holst","year":"2010","journal-title":"Results Probl Cell Differ."},{"key":"B8","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/289514a0","article-title":"Relationship of glicentin to proglucagon and glucagon in the porcine pancreas","volume":"289","author":"Moody","year":"1981","journal-title":"Nature."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.celrep.2017.10.034","article-title":"Circulating glucagon 1-61 regulates blood glucose by increasing insulin secretion and hepatic glucose production","volume":"21","author":"Wewer Albrechtsen","year":"2017","journal-title":"Cell Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/282260a0","article-title":"Identification and processing of proglucagon in pancreatic islets","volume":"282","author":"Patzelt","year":"1979","journal-title":"Nature."},{"key":"B11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1172\/JCI115012","article-title":"Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine","volume":"87","author":"Orskov","year":"1991","journal-title":"J Clin Invest."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.celrep.2018.10.018","article-title":"Insulin secretion depends on intra-islet glucagon signaling","volume":"25","author":"Svendsen","year":"2018","journal-title":"Cell Rep."},{"key":"B13","first-page":"223","article-title":"Glucagon and the control of appetite","volume-title":"Glucagon III. Handbook of Experimental Pharmacology 123","author":"Geary","year":"1996"},{"key":"B14","doi-asserted-by":"publisher","first-page":"ijms20215416","DOI":"10.3390\/ijms20215416","article-title":"Methods and guidelines for measurement of glucagon in plasma","volume":"20","author":"Holst","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"E302","DOI":"10.1152\/ajpendo.00119.2016","article-title":"Dynamics of glucagon secretion in mice and rats revealed using a validated sandwich ELISA for small sample volumes","volume":"311","author":"Wewer Albrechtsen","year":"2016","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/0016-5085(83)90388-8","article-title":"Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin\u2013current status","volume":"84","author":"Holst","year":"1983","journal-title":"Gastroenterology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"8621","DOI":"10.1016\/S0021-9258(18)68350-4","article-title":"Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine","volume":"263","author":"Buhl","year":"1988","journal-title":"J Biol Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.11613\/BM.2017.034","article-title":"Insights on glicentin, a promising peptide of the proglucagon family","volume":"27","author":"Raffort","year":"2017","journal-title":"Biochem Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/77535","article-title":"The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake","volume":"6","author":"Tang-Christensen","year":"2000","journal-title":"Nat Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1146\/annurev-physiol-021113-170404","article-title":"The role of gut hormone peptide YY in energy and glucose homeostasis: twelve years on","volume":"76","author":"Manning","year":"2014","journal-title":"Annu Rev Physiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.peptides.2017.09.018","article-title":"Oxyntomodulin: actions and role in diabetes","volume":"100","author":"Holst","year":"2018","journal-title":"Peptides."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5356","DOI":"10.1210\/endo.140.11.7143","article-title":"Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine","volume":"140","author":"Hansen","year":"1999","journal-title":"Endocrinology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1007\/s00125-011-2168-7","article-title":"Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs","volume":"54","author":"Hjollund","year":"2011","journal-title":"Diabetologia."},{"key":"B24","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s00125-005-1705-7","article-title":"Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors","volume":"48","author":"Holst","year":"2005","journal-title":"Diabetologia."},{"key":"B25","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/nature00887","article-title":"Gut hormone PYY(3-36) physiologically inhibits food intake","volume":"418","author":"Batterham","year":"2002","journal-title":"Nature."},{"key":"B26","doi-asserted-by":"publisher","first-page":"12455","DOI":"10.14814\/phy2.12455","article-title":"The anorexic hormone Peptide YY3-36 is rapidly metabolized to inactive Peptide YY3-34 in vivo","volume":"3","author":"Torang","year":"2015","journal-title":"Physiol Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"R866","DOI":"10.1152\/ajpregu.00394.2015","article-title":"In vivo and in vitro degradation of peptide YY3-36 to inactive peptide YY3-34 in humans","volume":"310","author":"Torang","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.brainres.2005.03.011","article-title":"The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway","volume":"1044","author":"Abbott","year":"2005","journal-title":"Brain Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/cphy.c180013","article-title":"Physiology of the incretin hormones, GIP and GLP-1 - regulation of release and post-translational modifications","volume":"9","author":"Holst","year":"2019","journal-title":"Compr Physiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1152\/physrev.00025.2016","article-title":"The new biology and pharmacology of glucagon","volume":"97","author":"Muller","year":"2017","journal-title":"Physiol Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.2217\/bmm-2016-0090","article-title":"The biology of glucagon and the consequences of hyperglucagonemia","volume":"10","author":"Wewer Albrechtsen","year":"2016","journal-title":"Biomark Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1210\/er.2018-00251","article-title":"The liver-alpha-cell axis and type 2 diabetes","volume":"40","author":"Wewer Albrechtsen","year":"2019","journal-title":"Endocr Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2337\/db16-0994","article-title":"Glucagon and amino acids are linked in a mutual feedback cycle: the liver-alpha-cell axis","volume":"66","author":"Holst","year":"2017","journal-title":"Diabetes."},{"key":"B34","doi-asserted-by":"publisher","first-page":"G91","DOI":"10.1152\/ajpgi.00216.2017","article-title":"Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes","volume":"314","author":"Wewer Albrechtsen","year":"2018","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"dgaa061","DOI":"10.1210\/clinem\/dgaa061","article-title":"Oxyntomodulin and glicentin may predict the effect of bariatric surgery on food preferences and weight loss","volume":"105","author":"Nielsen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e0145890","DOI":"10.1371\/journal.pone.0145890","article-title":"Minor contribution of endogenous GLP-1 and GLP-2 to postprandial lipemia in obese men","volume":"11","author":"Matikainen","year":"2016","journal-title":"PLoS ONE."},{"key":"B37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Muller","year":"2019","journal-title":"Mol Metab."},{"key":"B38","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/0167-0115(83)90712-7","article-title":"Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity","volume":"7","author":"Holst","year":"1983","journal-title":"Int J Obes."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.2337\/db07-1315","article-title":"Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients","volume":"57","author":"Muscelli","year":"2008","journal-title":"Diabetes."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/sj.ijo.0801655","article-title":"The role of postprandial releases of insulin and incretin hormones in meal-induced satiety-effect of obesity and weight reduction","volume":"25","author":"Verdich","year":"2001","journal-title":"Int J Obes Relat Metab Disord."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.2337\/db14-1751","article-title":"GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO study","volume":"64","author":"Faerch","year":"2015","journal-title":"Diabetes."},{"key":"B42","doi-asserted-by":"publisher","first-page":"242","DOI":"10.2337\/dc13-1283","article-title":"GLP-1 responses are heritable and blunted in acquired obesity with high liver fat and insulin resistance","volume":"37","author":"Matikainen","year":"2014","journal-title":"Diabetes Care."},{"key":"B43","doi-asserted-by":"publisher","first-page":"7750","DOI":"10.1210\/jcem.86.8.7750","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetic patients","volume":"8","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"key":"B44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00125-010-1896-4","article-title":"Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?","volume":"54","author":"Nauck","year":"2011","journal-title":"Diabetologia."},{"key":"B45","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00125-013-2841-0","article-title":"Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies","volume":"56","author":"Calanna","year":"2013","journal-title":"Diabetologia."},{"key":"B46","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/j.1464-5491.2008.02579.x","article-title":"Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes","volume":"25","author":"Hojberg","year":"2008","journal-title":"Diabet Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1056\/NEJMoa030204","article-title":"Inhibition of food intake in obese subjects by peptide YY3-36","volume":"349","author":"Batterham","year":"2003","journal-title":"N Engl J Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1210\/jc.2002-021873","article-title":"Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus","volume":"88","author":"Vilsboll","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"B50","doi-asserted-by":"publisher","first-page":"E1248","DOI":"10.1152\/ajpendo.00569.2013","article-title":"Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men","volume":"306","author":"Schmidt","year":"2014","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"B51","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1210\/en.2005-0237","article-title":"Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively","volume":"146","author":"Neary","year":"2005","journal-title":"Endocrinology."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.2337\/dc19-0449","article-title":"Combined GLP-1, oxyntomodulin, and peptide YY improves body weight and glycemia in obesity and prediabetes\/type 2 diabetes: a randomized, single-blinded, placebo-controlled study","volume":"42","author":"Behary","year":"2019","journal-title":"Diabetes Care."},{"key":"B53","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"NEJMoa2107519","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"2021","author":"Frias","year":"2021","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"dgaa327","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","first-page":"JCI146353","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"J Clin Invest"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2022.964406\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T05:54:35Z","timestamp":1659592475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2022.964406\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":56,"alternative-id":["10.3389\/fnut.2022.964406"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2022.964406","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]},"article-number":"964406"}}